01—Abstract
Summary
Summary of the 10-Q filed August 4, 2026. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences Corporation (EW) reported solid financial performance for the six months ended June 30, 2026.
Net sales increased by 15.1% year-over-year to $3.39 billiona, driven by strong growth in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) products, particularly the Edwards SAPIEN platform and PASCAL/EVOQUE systems. The company completed two strategic acquisitions: Autus Valve Technologies, Inc. in February 2026 and consolidated a Variable Interest Entity (VIE) in May 2026, reflecting investments in future growth. While revenue and gross profit showed positive trends, the company experienced a significant increase in its effective tax rate to 36.4% for the six months ended June 30, 2026, up from 16.1% in the prior year.
This increase was primarily attributed to new California budget legislation impacting tax credits and the initial impact of global minimum tax rules (Pillar Two). Despite this, the company's operating cash flow remained strong, providing sufficient liquidity for its ongoing operations and strategic initiatives. Investors should monitor the impact of evolving tax regulations and potential future litigation outcomes.
02—Key points
Key Highlights
- Net sales increased by 15.1% to $3.39 billion for the first six months of 2026, driven by TAVR and TMTT product growth.
- Acquired Autus Valve Technologies, Inc. for $128.9 million and consolidated a VIE, signaling strategic investments in innovation and growth.
- Gross profit increased, but gross profit margin slightly decreased due to foreign currency fluctuations, partially offset by lower manufacturing expenses.
- Diluted earnings per share decreased due to a significant increase in the effective tax rate.
- The effective tax rate rose to 36.4% for the six months ended June 30, 2026, mainly due to new California tax legislation and global minimum tax (Pillar Two) impacts.
- Operating cash flow was strong at $695.7 million for the six months ended June 30, 2026, an increase from the prior year.
- The company continues to face and actively defend against several ongoing litigation matters, with management not currently expecting a material adverse effect on its overall financial condition.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2026, Edwards Lifesciences kept $0.14.
- Revenue$1.74B100.0%
- Cost of revenue−$392.4M22.5%
- Gross profit$1.35B77.5%
- Operating costs−$835.4M48.0%
- Operating income$513.2M29.5%
- Interest, other & tax−$271.8M15.6%
- Net income$241.4M13.9%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed August 4, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $1.74B$1.53B | +13.6% |
| Cost of Revenue | $392.40M$344.40M | +13.9% |
| Gross Profit | $1.35B$1.19B | +13.5% |
| R&D Expenses | $278.90M$276.20M | +1.0% |
| SG&A Expenses | $561.20M$502.00M | +11.8% |
| Operating Income | $513.20M$411.20M | +24.8% |
| Net Income | $241.40M$331.50M | −27.2% |
| EPS (Basic) | $0.42$0.57 | −26.3% |
| EPS (Diluted) | $0.42$0.56 | −25.0% |
| Shares Outstanding (Basic) | 576.40M587.00M | −1.8% |
| Shares Outstanding (Diluted) | 577.60M587.90M | −1.8% |
05—Questions
Frequently Asked Questions
What were the primary drivers of Edwards Lifesciences' net sales growth in the first half of 2026?
Net sales growth was primarily driven by strong performance in the Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product groups. Specific products contributing to this growth include the Edwards SAPIEN platform, the PASCAL transcatheter edge-to-edge repair system, the EVOQUE tricuspid valve replacement system, and the SAPIEN M3 mitral valve replacement system. Growth was observed across key geographic segments, including the United States and Europe.
What is causing the significant increase in Edwards Lifesciences' effective tax rate?
The effective tax rate for the first six months of 2026 increased significantly to 36.4% compared to 16.1% in the prior year. This rise is mainly due to two factors: (1) new California budget legislation enacted in June 2026, which permanently limits the utilization of business tax credits and necessitated a $188.2 million valuation allowance against certain deferred tax assets, and (2) the initial impact of global minimum tax rules (Pillar Two), which is expected to add approximately $50.0 million in tax expense for 2026 before offsets.
How did the company's recent acquisitions and business combinations impact the financials?
Edwards Lifesciences completed two significant transactions: the acquisition of Autus Valve Technologies, Inc. in February 2026 for $128.9 million, and the consolidation of a Variable Interest Entity (VIE) in May 2026. These acquisitions are expected to drive future growth. The consolidation of the VIE resulted in the recognition of $139.6 million in goodwill and $161.5 million in in-process R&D, while the Autus acquisition generated $52.0 million in goodwill and $102.9 million in in-process R&D. The company also recognized gains from the remeasurement of previously held interests in both transactions.
What is the company's outlook on its legal proceedings and potential liabilities?
Edwards Lifesciences is involved in several ongoing litigation matters, including patent infringement claims and securities class actions. As of June 30, 2026, the company had accrued an aggregate estimated liability of $56.9 million for outstanding legal proceedings. Management believes that these lawsuits, in aggregate, are not expected to have a material adverse effect on the company's overall financial condition, results of operations, or cash flows. However, they acknowledge that the resolution of one or more matters could materially impact financial results in a specific reporting period. Specific attention is drawn to a significant IRS examination concerning transfer pricing for tax years 2015-2017, with a potential tax expense of approximately $269.3 million plus interest, which the company plans to contest judicially.
06—Continue